Roche to acquire Spark with a 122% premium of it previous closing price, with a deal valued of ~$4.3 billion.
Spark won FDA’s first approval on gene therapy for genetic disease more than one year ago, treating retinal dystrophy (by mutations on the RPE65 gene) with LUXTURNA. The treatment carries a list price of $850,000, or $425,000 per eye.
Besides, Spark Therapeutics has SPK-8011 in clinical trials, a novel gene therapy for the treatment of haemophilia A, which is expected to start Phase 3 in 2019.
Here is a brief video of the procedure for it first patient in US last March.